Free Worldwide Shipping ($300+) | Credit Cards Accepted | 6% Off Crypto
Menu
Cart
tirzepatide 20 mg vial

Tirzepatide 20mg – 10 Vial Box

$655.00

Cost per vial $: 65.5

Bulk discounts
Quantity Bulk Discount Price
2 5% $622.25
3-5 8% $602.60
6-10 11% $582.95
SKU: TIR20 Category:

Description

Tirzepatide is a peptide that helps regulate blood sugar levels and support weight management by mimicking natural hormones that control appetite and glucose balance. It’s commonly used to promote weight loss and improve glycemic control in type 2 diabetes patients. Tirzepatide is the generic peptide version of Mounjaro and Zepbound.

Minimum order quantity: one box (10 vials x 20 mg). All orders are shipped wholesale in unbranded packaging.

Additional information

Purity

≥99.0%
Molar Mass

4813.527 g·mol
Molecular Formula

C₂₂₅H₃₄₈N₄₈O₆₈
Sequence

H-Tyr-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Aib-Leu-Asp-Lys-Ile-Ala-Gln-Lys(Eicosanedioyl-isoGlu-PEG2-PEG2)-Ala-Phe-Val-Gln-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2
Cost per vial $

65.5
  1. Min, Thinzar, and Stephen C. Bain. "The role of tirzepatide, dual GIP and GLP-1 receptor agonist, in the management of type 2 diabetes: the SURPASS clinical trials." Diabetes Therapy 12.1 (2021): 143-157.
  2. Jastreboff, Ania M., et al. "Tirzepatide once weekly for the treatment of obesity." New England Journal of Medicine 387.3 (2022): 205-216.
  3. Frías, Juan P., et al. "Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes." New England Journal of Medicine 385.6 (2021): 503-515.
  4. Syed, Yahiya Y. "Tirzepatide: first approval." Drugs 82.11 (2022): 1213-1220.
  5. Rosenstock, Julio, et al. "Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial." The Lancet 398.10295 (2021): 143-155.
  6. Rosenstock, Julio, et al. "Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial." The Lancet 398.10295 (2021): 143-155.
  7. Chavda, Vivek P., et al. "Tirzepatide, a new era of dual-targeted treatment for diabetes and obesity: a mini-review." Molecules 27.13 (2022): 4315.

Tirzepatide CoA 2024

Tirzepatide HPLC

Related products